Aging Frailty
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
LongeveronMIAMI, FL
2 programs1
1
Longeveron Mesenchymal Stem CellsPhase 21 trial
Longeveron Mesenchymal Stem CellsPhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
LongeveronLongeveron Mesenchymal Stem Cells
LongeveronLongeveron Mesenchymal Stem Cells
Clinical Trials (2)
Total enrollment: 212 patients across 2 trials
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
Start: Jul 2017Est. completion: Sep 2021150 patients
Phase 2Completed
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
Start: Nov 2016Est. completion: Sep 202262 patients
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space